OBJECTIVE:To determine the demographics and associated clinical features of Omani keratoconus patients presenting to the Ministry of Defence Hospital (MODH) in Muscat.METHODS:This is a retrospective, descriptive study whereby the electronic medical records of all Omani keratoconus patients presenting to the MODH between January 2011 and December 2015 were reviewed. Demographic details, corrected distance visual acuity, refraction, corneal topography, pachymetry, and treatment received were all documented.RESULTS:There were 458 new keratoconus patients (257 males, 201 females) comprising a total of 893 eyes with a mean age of 20 years ± 5.6 (standard deviation) (range 6–46 years). On their first visit, 35% of eyes had spectacle-corrected distance visual acuity <0.5 logarithm of the minimum angle of resolution (LogMAR), 38% had central corneal thickness <450 um, and 25% had a mean keratometry more than 53 Diopter (D). According to the Amsler-Krumeich classification, 37%, 30%, 18%, and 16% of eyes classified into stages I, II, III, and IV, respectively. The severity of keratoconus did not correlate with the age of patients (rs = −0.13, P < 0.05). Over the 5-year period of the study, 502 eyes were fitted with rigid gas permeable lenses with 91% achieving the vision of 0.1 LogMAR or better, 22% of eyes underwent collagen cross linking, 3% underwent intracorneal ring segments implantation, and 4% underwent corneal grafting.CONCLUSION:A significant proportion of Omani keratoconus patients seen in the MODH showed advanced disease on their first visit. There was no correlation between severity and age suggesting that keratoconus can progress quickly in our pediatric group. Population-based studies are an important next step. Meanwhile, early detection and timely interventions to limit the burden of the disease are crucial.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.